David Einstein, MD
Beth Israel Deaconess Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Einstein, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:08 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07925333 · Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney CancerBeth Israel Deaconess Medical Center · not yet recruiting · Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer) · principal investigator
- Early Ph1NCT05683964 · Androgen Receptor Signaling and Prostate-Specific Membrane Antigen ExpressionBeth Israel Deaconess Medical Center · active not recruiting · Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) · principal investigator
- Ph2NCT04781374 · Neratinib in Patients With Metastatic Castration-Resistant Prostate CancerBeth Israel Deaconess Medical Center · withdrawn · Metastatic Prostate Adenocarcinoma, Castration-resistant Prostate Cancer, Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.